Could be? Idk, CTMX has beaten Earnings in the last four Quarts.will see today what big sharks decide for this stock and I will jump with them before the earning day, if they decide to short I will follow.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.358 CHF
28.94 M CHF
125.43 M CHF
78.64 M
About CytomX Therapeutics, Inc.
Sector
Industry
CEO
Sean A. McCarthy
Website
Headquarters
South San Francisco
Founded
2010
FIGI
BBG00LVD6QG9
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
CTMX Opportunity to hit 3.8 - 5.7 mark after the huge dropTheir recent study data ir.cytomx.com
Their ER PR ir.cytomx.com
Summary:
CytomX Therapeutics announces positive initial Phase 1a dose escalation data for monotherapy CX-904, a PROBODY® T-Cell Engager, demonstrating a favorable safety profile and encouraging efficacy in advanced pancreatic cancer
Stock Idea: $CTMX (8 Feb 2023)$CTMX
- Power-play setup on another Biotech stock
- Gapped up on strong volume on news of partnership with Moderna
- Been tightening up. Broke above downtrend resistance on Mon. Inside-day bar on Tue
CytomX Therapeutics Announces FDA Clearance of Investigational NCTMX: CytomX Therapeutics, Inc.
2022-01-19 08:00:00
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
Possible bullish runI am predicting a possible bullish run of over 300% given past historical data. When looking at the charts you’ll notice recurrent trends. First a price bearish downtrend that lasts a few months followed by a sudden 75% bullish run which is immediately followed by a sharp price dip of over 50%. Pric
BULLISHEngages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Shareholders may be thrilled to learn that t
CYTOMX THERAPEUTICS INChigh probability next target 7.94
if the price strongly breaks the horizontal white line and closes above high probability next target 10.60
if you need an analysis do not hesitate to contact me.
don't forget to subscribe to receive updates if you find interesting what I do
CTMX trend reversal?The overall trend is down but recently strong bullish activity is happening. The share price shattered past the last stance of resistance around $11.50 and the last round of support is around $9.00. Can the bulls keep it up?
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of 6C1 is 0.964 CHF — it has decreased by −39.60% in the past 24 hours. Watch CYTOMX THERAPEUTIC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CYTOMX THERAPEUTIC stocks are traded under the ticker 6C1.
6C1 stock has fallen by −39.60% compared to the previous week, the month change is a −39.60% fall, over the last year CYTOMX THERAPEUTIC has showed a −39.60% decrease.
We've gathered analysts' opinions on CYTOMX THERAPEUTIC future price: according to them, 6C1 price has a max estimate of 4.11 CHF and a min estimate of 2.05 CHF. Watch 6C1 chart and read a more detailed CYTOMX THERAPEUTIC stock forecast: see what analysts think of CYTOMX THERAPEUTIC and suggest that you do with its stocks.
6C1 stock is 65.56% volatile and has beta coefficient of 1.56. Track CYTOMX THERAPEUTIC stock price on the chart and check out the list of the most volatile stocks — is CYTOMX THERAPEUTIC there?
Today CYTOMX THERAPEUTIC has the market capitalization of 62.42 M, it has decreased by −11.38% over the last week.
Yes, you can track CYTOMX THERAPEUTIC financials in yearly and quarterly reports right on TradingView.
CYTOMX THERAPEUTIC is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
6C1 earnings for the last quarter are 0.20 CHF per share, whereas the estimation was −0.18 CHF resulting in a 212.65% surprise. The estimated earnings for the next quarter are 0.11 CHF per share. See more details about CYTOMX THERAPEUTIC earnings.
CYTOMX THERAPEUTIC revenue for the last quarter amounts to 34.60 M CHF, despite the estimated figure of 11.84 M CHF. In the next quarter, revenue is expected to reach 31.44 M CHF.
6C1 net income for the last quarter is 17.14 M CHF, while the quarter before that showed 4.86 M CHF of net income which accounts for 252.68% change. Track more CYTOMX THERAPEUTIC financial stats to get the full picture.
No, 6C1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 10, 2025, the company has 121 employees. See our rating of the largest employees — is CYTOMX THERAPEUTIC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CYTOMX THERAPEUTIC EBITDA is 24.31 M CHF, and current EBITDA margin is 19.38%. See more stats in CYTOMX THERAPEUTIC financial statements.
Like other stocks, 6C1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYTOMX THERAPEUTIC stock right from TradingView charts — choose your broker and connect to your account.